Q4 2024 Earnings Call Transcript March 27, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...

Good morning and welcome to PDS Biotech's 4th quarter in full year 2024 earnings conference call. Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's 2024 results and clinical ...

Analysts anticipate PDS Biotechnology to report an earnings per share (EPS) of $-0.30. Anticipation surrounds PDS ...

PDS Biotechnology Corp (PDSB) reports a reduced net loss and significant clinical progress, but faces funding hurdles for ongoing trials.

H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on PDS Biotechnology (PDSB) to $13 from $21 and keeps a Buy rating on ...

We are pleased with the progress made over the past year and in recent weeks, culminating with the initiation of our VERSATILE-003 Phase 3 ...

PDS BIOTECHNOLOGY ($PDSB) posted quarterly earnings results on Thursday, March 27th. The company reported earnings of -$0.21 per share, beating estimates of -$0.28 by ...

Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., March 27 ...

PDS Biotechnology Corp (PDSB) reported a net loss of $37.6 million for 2024, an improvement from the $42.9 million loss in 2023, during its Q4 2024 earnings call. The company’s efforts to reduce ...